Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.96
+0.29 (1.34%)
At close: Mar 7, 2025, 4:00 PM
21.85
-0.11 (-0.50%)
After-hours: Mar 7, 2025, 8:38 PM EST
Catalyst Pharmaceuticals Revenue
In the year 2024, Catalyst Pharmaceuticals had annual revenue of $491.73M with 23.49% growth. Catalyst Pharmaceuticals had revenue of $141.82M in the quarter ending December 31, 2024, with 28.26% growth.
Revenue (ttm)
$491.73M
Revenue Growth
+23.49%
P/S Ratio
5.29
Revenue / Employee
$2,716,762
Employees
181
Market Cap
2.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 491.73M | 93.53M | 23.49% |
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CPRX News
- 5 days ago - Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire
- 6 days ago - Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges - Seeking Alpha
- 10 days ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 25 days ago - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - GlobeNewsWire
- 4 weeks ago - Catalyst Remains a Big Money Favorite - FXEmpire
- 6 weeks ago - Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies - GlobeNewsWire
- 6 weeks ago - Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - GlobeNewsWire